| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910495196703321 |
|
|
Titolo |
Management of pancreatic cancer and cholangiocarcinoma / / Hiroyuki Isayama, Yousuke Nakai, Takashi Sasaki, editors |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Gateway East, Singapore : , : Springer, , [2021] |
|
©2021 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (318 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Pancreas - Cancer - Treatment |
Càncer de pàncrees |
Tracte biliar |
Llibres electrònics |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Preface -- Contents -- Part I: Current Topics in Epidemiology and Examinations of Pancreatic Cancer and Cholangiocarcinoma -- 1: Risk Factors for Pancreatic Cancer and Cholangiocarcinoma -- 1.1 Risk Factors for Pancreatic Cancer -- 1.1.1 Introduction -- 1.1.2 Genetic Factors -- 1.1.3 Pancreatic Disorders (Cystic Lesions and Chronic Pancreatitis) -- 1.1.4 Epidemiological Factors -- 1.1.5 Microbiome -- 1.1.6 Discussion -- 1.2 Risk Factors for Cholangiocarcinoma -- 1.2.1 Introduction -- 1.2.2 Microbiome (Infectious Diseases) -- 1.2.3 Genetic Factors -- 1.2.4 Pancreatobiliary and Inflammatory Disorders -- 1.2.5 Epidemiological Factors -- 1.2.6 Discussion -- References -- 2: Detection Strategies and Examination of Early Pancreatic Cancer -- 2.1 Introduction -- 2.2 Clinical Features and Image Findings of Early-Stage PC -- 2.3 Cytological Diagnosis of Early-Stage PC -- 2.4 Pathological Features of Early-Stage PC -- 2.5 Statements and Detection Strategies of Early-Stage PC in Japan -- 2.6 Collaborations Between Specialists and General Practitioners for Early-Stage PC in Japan -- References -- 3: Biomarkers for Pancreatic Cancer and Cholangiocarcinoma -- 3.1 Introduction -- 3.2 Currently Used Biomarkers for PDAC and CCA -- 3.3 Other Protein Markers for PDAC |
|
|
|
|
|
|
|
|
|
and CCA -- 3.4 Circulating Tumor Cells -- 3.5 Extracellular Vesicles -- 3.6 Biomarker-Based Selection of Targeted Therapies -- 3.7 Conclusion and Future Perspectives -- References -- 4: Recent Advances of Precision Medicine in Pancreatic Cancer and Cholangiocarcinoma -- 4.1 Introduction -- 4.2 Features of Two Reimbursed CGP Tests -- 4.3 Required Tissue Samples -- 4.4 Liquid Biopsy -- 4.5 Eligible Patients for CGP Test and Optimal Timing of Its Application -- 4.6 Clinical Benefit of CGP Tests in Pancreatic Cancer. |
4.7 Clinical Benefit of CGP Tests in Biliary Tract Cancer -- References -- Part II: Anti-cancer Treatments for Pancreatic Cancer -- 5: Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer -- 5.1 Introduction -- 5.2 Metastatic Pancreatic Cancer -- 5.2.1 FOLFIRINOX -- 5.2.2 Gemcitabine Plus Nab-Paclitaxel -- 5.2.3 Selection Between FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel -- 5.2.4 Intraperitoneal Chemotherapy in Patients with Peritoneal Dissemination -- 5.3 Locally Advanced Pancreatic Cancer -- 5.4 The Role of Monotherapy -- 5.5 Second-Line Chemotherapy -- 5.6 Future Perspective -- References -- 6: Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer -- 6.1 Introduction -- 6.2 Preoperative Estimation for Surgical Resectability -- 6.3 Potentially Resectable Tumors -- 6.4 Prospective Studies for NAT and Adjuvant Therapy -- 6.5 Optimal Agent or Regimens for NAT for Potentially Resectable PA -- 6.6 Optimal Regimens for NAT: Chemotherapy or CRT? -- 6.7 Optimal Duration for NAT -- 6.8 Conclusion -- References -- 7: Adjuvant Chemotherapy for Pancreatic Cancer -- 7.1 History of Postoperative Adjuvant Chemotherapy -- 7.1.1 ESPAC-01 -- 7.1.2 CONKO-001 -- 7.1.3 RTOG 9704 -- 7.1.4 CapRI -- 7.1.5 ESPAC-3 -- 7.1.6 JASPAC 01 -- 7.1.7 ESPAC-4 -- 7.1.8 PRODIGE 24-ACCORD/CCTG PA.6 -- 7.1.9 APACT -- 7.2 Future Perspectives -- 7.3 Conclusion -- References -- 8: Conversion Surgery in Pancreatic Cancer -- 8.1 Introduction -- 8.2 Definition of Unresectable Pancreatic Cancer -- 8.3 Conversion Surgery for LA-PDAC -- 8.4 Conversion Surgery for Metastatic PDAC -- 8.5 Techniques of Conversion Surgery for PDAC -- 8.6 Summary -- 8.7 Conclusion -- References -- 9: Radiotherapy for Pancreatic Cancer -- 9.1 Introduction -- 9.2 Modalities for Radiotherapy -- 9.2.1 Advances in Radiotherapy. |
9.2.1.1 Three-Dimensional Conformal Radiation Therapy: 3D-CRT -- 9.2.1.2 Intensity Modulated Radiotherapy: IMRT -- 9.2.1.3 Image-Guided Radiotherapy: IGRT -- 9.2.1.4 Stereotactic Irradiation: SRI -- 9.2.1.5 Charged Particle Therapy (Proton Beam Radiotherapy, Heavy-Ion Radiotherapy) -- 9.3 Radiation Therapy for Pancreatic Cancer -- 9.3.1 Resected Pancreatic Cancer: Adjuvant Approach -- 9.3.2 Potentially Resectable Pancreatic Cancer: PRPC -- 9.3.3 Borderline Resectable Pancreatic Cancer: BRPC -- 9.3.4 Locally Advanced Pancreatic Cancer: LAPC -- 9.4 Particle Therapy -- 9.4.1 CIRT in Potentially Resectable Pancreatic Cancer -- 9.4.2 Proton Beam Therapy in Locally Advanced Pancreatic Cancer -- 9.4.3 CIRT in Locally Advanced Pancreatic Cancer -- 9.4.4 Perspective -- References -- Part III: Anti-cancer Treatments for Cholangiocarcinoma -- 10: Chemotherapy for Unresectable Cholangiocarcinoma -- 10.1 Introduction -- 10.2 First-Line Chemotherapy -- 10.2.1 GEM + CDDP -- 10.2.2 GEMOX -- 10.2.3 GEM + S-1 -- 10.2.4 GEM + CDDP + S-1 -- 10.2.5 XELOX (Capecitabine + Oxaliplatin) -- 10.2.6 Other Randomized Controlled Studies -- 10.2.7 Interesting Regimens from Phase II Studies -- 10.3 Second-Line Chemotherapy -- 10.3.1 mFOLFOX Versus BSC (ABC-06 Study) -- 10.3.2 Ivosidenib Versus BSC (ClarIDHy) -- 10.3.3 Regorafenib Versus BSC (REACHIN) -- 10.3.4 |
|
|
|
|
|
|
|
Other Randomized Controlled Studies -- 10.3.5 Interesting Regimens from Phase II Studies -- 10.4 Clinical Trials -- 10.5 Conclusions -- References -- 11: Adjuvant Chemotherapy for Cholangiocarcinoma -- 11.1 Introduction -- 11.2 Fluorouracil + Leucovorin -- 11.3 Gemcitabine + Oxaliplatin -- 11.4 Capecitabine -- 11.5 Gemcitabine -- 11.6 Gemcitabine + Capecitabine -- 11.7 Meta-analysis -- 11.8 Ongoing Clinical Trial -- 11.9 Future Direction -- References. |
12: Neoadjuvant Therapy and Conversion Surgery for Cholangiocarcinoma -- 12.1 Introduction -- 12.2 Neoadjuvant Chemotherapy for Cholangiocarcinoma -- 12.2.1 Need for Neoadjuvant Chemotherapy -- 12.2.2 Reports on Neoadjuvant Therapy for Cholangiocarcinoma -- 12.2.3 Prospective Studies of Neoadjuvant Therapy for Cholangiocarcinoma -- 12.2.4 Patient Selection for Neoadjuvant Therapy for Cholangiocarcinoma -- 12.3 Conversion Surgery for Cholangiocarcinoma -- 12.3.1 Definition of Resectability for Cholangiocarcinoma -- 12.3.2 Reports on Conversion Surgery for Locally Advanced Cholangiocarcinoma -- 12.3.3 Reports on Conversion Surgery for Cholangiocarcinoma with Distant Metastasis or Recurrent Cholangiocarcinoma -- 12.3.4 Conversion Hepatectomy for Liver Metastasis of Distal Bile Duct Cancer -- 12.4 Conclusion -- References -- 13: Radiotherapy for Cholangiocarcinoma -- 13.1 Introduction -- 13.2 Techniques for External Body Radiotherapy -- 13.2.1 3D-CRT and SBRT -- 13.2.2 IMRT -- 13.2.3 PT -- 13.3 RT for Cholangiocarcinoma -- 13.3.1 IHCC -- 13.3.1.1 Adjuvant Radiotherapy -- 13.3.1.2 Neoadjuvant Radiotherapy -- 13.3.1.3 Definitive RT -- 13.3.2 Extrahepatic Cholangiocarcinoma -- 13.3.2.1 Adjuvant Radiotherapy -- 13.3.2.2 Neoadjuvant Radiotherapy -- 13.3.2.3 Definitive RT -- 13.4 RT Toxicity -- 13.4.1 Radiation-Induced Liver Disease -- 13.4.2 Biliary Tracts -- 13.4.3 Gastrointestinal Tracts -- References -- Part IV: New Treatment for Pancreatic Cancer and Cholangiocarcinoma -- 14: Precision Medicine for Pancreatic Cancer and Cholangiocarcinoma -- 14.1 Introduction -- 14.2 Precision Medicine for Pancreatic Cancer -- 14.2.1 Genetic Landscape of Pancreatic Ductal Adenocarcinoma (Fig. 14.1) -- 14.2.2 Pancreatic Ductal Adenocarcinoma Harboring Germline BRCA1/2 Mutation. |
14.2.3 Pancreatic Ductal Adenocarcinoma Harboring KRAS Mutation -- 14.2.4 Pancreatic Ductal Adenocarcinoma of KRAS Wild-Type -- 14.3 Precision Medicine for Biliary Tract Cancer -- 14.3.1 Genetic Landscape of Biliary Tract Cancer (Fig. 14.2) -- 14.3.2 Biliary Tract Cancer Harboring FGFR2 Rearrangement -- 14.3.3 Biliary Tract Cancer Harboring IDH1 Mutation -- 14.3.4 Biliary Tract Cancer with HER2/neu Gene Amplification or Overexpression -- 14.3.5 BRAF Mutation -- 14.3.6 Other Genomic Alterations and Targeted Therapy -- 14.4 Conclusions and Future Perspectives -- References -- 15: Immunotherapy for Pancreatic Cancer and Cholangiocarcinoma -- 15.1 Introduction -- 15.2 Types of ICIs -- 15.3 Mechanism of ICIs -- 15.4 Biomarker of ICIs -- 15.5 Tumor Microenvironment -- 15.6 ICIs in Pancreatic Cancer -- 15.6.1 Anti-PD-L1 Antibody -- 15.6.1.1 BMS-936559 -- 15.6.2 Anti-CTLA-4 Antibody -- 15.6.2.1 Ipilimumab -- 15.6.3 Anti-PD-L1 Antibody Plus Anti-CTLA-4 Antibody -- 15.6.3.1 Durvalumab Plus Tremelimumab -- 15.6.4 Combination with a Cytotoxic Agent -- 15.6.4.1 Nivolumab -- 15.6.4.2 Durvalumab with Tremelimumab -- 15.6.5 Combination with Radiation -- 15.6.6 Ongoing Trials -- 15.7 ICIs in Biliary Tract Cancer -- 15.7.1 Anti-PD-1 Antibody -- 15.7.1.1 Pembrolizumab -- 15.7.1.2 Nivolumab -- 15.7.2 Dual Checkpoint Inhibition -- 15.7.2.1 Nivolumab Plus Ipilimumab -- 15.7.3 Combination with a Cytotoxic |
|
|
|
|
|
|
|
|
Agent -- 15.7.3.1 Nivolumab -- 15.7.3.2 Durvalumab with and Without Tremelimumab -- 15.7.4 Antiangiogenic Therapy -- 15.7.4.1 Ramucirumab -- 15.7.4.2 Lenvatinib -- 15.7.5 Transforming Growth Factor β (TGF-β) -- 15.7.5.1 TGF-β Plus PD-L1 -- 15.7.6 Ongoing Trials -- References -- 16: Treatment Approach for Pancreatic Cancer with Peritoneal Dissemination -- 16.1 Introduction -- 16.2 Diagnostic Approach to Peritoneal Dissemination. |
16.3 Treatment Approach for Peritoneal Dissemination. |
|
|
|
|
|
| |